Gilead Sciences (GILD) stock price has risen on the news that Remdesivir saves more lives than it was previously thought. These results were revealed in a preliminary study.
Gilead Sciences (GILD) stock is slightly down despite the progress that the company made in testing of its remdesivir drug that can be used as the coronavirus treatment.
Gilead Sciences (GILD) stock is slightly down after the company set the Remdesivir price for developed countries at $390 per dose. Privately insured patients will be charged $520 per dose.
According to SVB Leerink analyst Geoffrey Porges, remdesivir price is likely to be $5,000 per course in the US, $4,000 per course in Europe, and around $2,000 in other markets. Gilead Sciences (GILD) stock keeps rising.
Gilead (GILD) stock price is rising slightly after the Japanese government indicated that it could grant approval to its remdesivir drug to be used in the fight with COVID-19.
50,000 units of Remdesivir are ready for shipment. The drug has passed initial trials and has been proven to be effective in the treatment of COVID-19. Gilead (GILD) stock price is increasing.
Following the positive news on the remdesivir trial, Gilead stock rebounded. Yesterday, GILD closed at $83.14 per share or 5.68% up. After hours, it added another 2.29% to trade at $85.04. The price is also rising today in the-premarket trading.
Gilead Sciences (GILD) stock price has moved up at the news that its drug remdesivir is used to treat coronavirus patients on ‘compassionate’ grounds.
As most stock markets continue bleeding out due to the coronavirus outbreak, three biotech stocks have been defying the urge as the companies are working on a vaccine or a cure for the deadly coronavirus.
While tech shares are suffering drops, coronavirus stocks are soaring, The pharma companies are actively working on the development of a new vaccine.